Functional Repair of Rat Corticospinal Tract Lesions	1
Functional Repair	1
Rat Corticospinal Tract Lesions	22
Permanent Survival of an Immunoincompatible Transplant Ying Li , Daqing Li	71
Permanent Survival	71
an Immunoincompatible Transplant Ying Li , Daqing Li	93
Geoffrey Raisman Cell transplantation	151
Geoffrey Raisman	151
Cell transplantation	169
one of the most promising strategies for repair of human spinal cord injuries	193
one	193
the most promising strategies for repair of human spinal cord injuries	200
the most promising strategies	200
repair of human spinal cord injuries	234
repair	234
human spinal cord injuries	244
Animal studies from a number of laboratories	272
Animal studies	272
a number of laboratories	292
a number	292
laboratories	304
transplantation of olfactory ensheathing cells cultured from biopsies of the olfactory bulb	333
transplantation	333
olfactory ensheathing cells cultured from biopsies of the olfactory bulb	352
olfactory ensheathing cells	352
biopsies of the olfactory bulb	394
biopsies	394
the olfactory bulb	406
axonal regeneration and remyelination	433
lost functions in spinal cord injuries	483
lost functions	483
spinal cord injuries	501
translation from small laboratory experimental injuries to the large spinal cord injuries encountered in human patients	527
translation	527
small laboratory experimental injuries to the large spinal cord injuries encountered in human patients	544
small laboratory experimental injuries	544
the large spinal cord injuries encountered in human patients	586
the large spinal cord injuries	586
human patients	632
the numbers of cells that can be obtained from a patient 's own olfactory bulb	647
the numbers	647
cells that can be obtained from a patient 's own olfactory bulb	662
cells	662
a patient 's own olfactory bulb	694
a patient 's	694
a serious	733
factor	752
removal of an olfactory bulb	773
removal	773
an olfactory bulb	784
invasive surgery and risks unilateral anosmia	811
invasive surgery	811
risks unilateral anosmia	832
risks	832
unilateral anosmia	838
We	858
xenografted mouse bulbar olfactory ensheathing cells immunoprotected by daily cyclosporine	878
xenografted mouse bulbar olfactory ensheathing cells	878
daily cyclosporine	950
forepaw	986
function	1003
rats with chronic C1/2 unilateral corticospinal tract lesions	1015
rats	1015
chronic C1/2 unilateral corticospinal tract lesions	1025
chronic C1/2	1025
unilateral corticospinal tract lesions	1038
function	1083
10 days	1117
cyclosporine	1126
Thirteen out of 13 rats	1154
Thirteen	1154
13 rats	1170
forepaw reaching	1209
forepaw	1209
Immunohistochemistry	1227
all cases	1262
neurofilamentpositive axons	1272
the lesion	1316
the grafted cells	1337
This	1382
cells	1413
bridges for axon regeneration	1433
bridges	1433
axon regeneration	1445
the lesion site their continued presence is no longer necessary for maintaining the restored function	1470
the lesion site	1470
their continued presence	1486
the restored function	1550
This	1573
the possibility	1585
the future	1609
a protocol of temporary immunoprotection	1620
a protocol	1620
temporary immunoprotection	1634
the use of the larger available numbers of immunoincompatible allografted cells or cell lines , which would avoid the need for removing a patient 's olfactory bulb	1677
the use	1677
the larger available numbers of immunoincompatible allografted cells or cell lines , which would avoid the need for removing a patient 's olfactory bulb	1688
the larger available numbers	1688
immunoincompatible allografted cells or cell lines	1720
immunoincompatible allografted cells	1720
cell lines	1760
the need	1790
a patient 's olfactory bulb	1812
a patient 's	1812
INTRODUCTION A number of studies	1841
INTRODUCTION A number	1841
studies	1866
transplanted olfactory ensheathing cells -LRB- OECs -RRB-	1890
transplanted olfactory ensheathing cells	1890
OECs	1932
axon regeneration , remyelination , and restoration of function	1949
axon regeneration	1949
remyelination	1968
restoration of function	1987
restoration	1987
function	2002
experimental spinal cord injuries -LRB- 7,8,10,15,21,22,27,28 -RRB-	2014
experimental spinal cord injuries	2014
7,8,10,15,21,22,27,28	2049
We	2073
a localized stereotaxic heat lesion completely destroying the adult rat corticospinal tract -LRB- CST -RRB-	2091
a localized stereotaxic heat lesion	2091
the adult rat corticospinal tract	2149
CST	2184
partial adjacent medial gray matter	2193
the C1/2 level	2245
this lesion	2271
forepaw reaching -LRB- DFR -RRB- on the lesion side	2293
forepaw	2293
-LRB- DFR -RRB- on the lesion side	2310
-LRB- DFR -RRB-	2310
the lesion side	2319
2 months after lesion	2358
2 months	2358
lesion	2373
injection of a suspension of a mixture of cultured adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2381
injection	2381
a suspension of a mixture of cultured adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2394
a suspension	2394
a mixture of cultured adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2410
a mixture	2410
adult bulbar OECs and olfactory nerve fibroblasts -LRB- ONFs -RRB-	2432
adult bulbar OECs	2432
olfactory nerve fibroblasts -LRB- ONFs -RRB-	2454
olfactory nerve fibroblasts	2454
ONFs	2483
DFR	2498
around 10 days -LRB- 12 -RRB-	2508
around 10 days	2508
12	2524
translation to clinical application	2533
translation	2533
clinical application	2548
removal of a patient 's olfactory bulb	2570
removal	2570
a patient 's olfactory bulb	2581
a patient 's	2581
a transdural endoscopic or intracranial approach	2621
the risk of unilateral anosmia	2676
the risk	2676
unilateral anosmia	2688
One way to obtain more cells and to avoid the problems of autograft biopsy	2708
One way	2708
more cells	2726
the problems of autograft biopsy	2750
the problems	2750
autograft biopsy	2766
a bank of allogeneic cells or cell lines -LRB- 16 -RRB-	2804
a bank	2804
allogeneic cells or cell lines -LRB- 16 -RRB-	2814
allogeneic cells or cell lines	2814
16	2846
transplants	2854
these	2867
an immune barrier	2903
A number of studies with immunoincompatible grafts	2922
A number	2922
studies with immunoincompatible grafts	2934
studies	2934
immunoincompatible grafts	2947
xenografted OECs immunoprotected with cyclosporine	2989
xenografted OECs	2989
cyclosporine	3027
axon regeneration and remyelination in the spinal cord -LRB- 10,11,18,19,29 -RRB-	3047
axon regeneration and remyelination	3047
the spinal cord -LRB- 10,11,18,19,29 -RRB-	3086
the spinal cord	3086
10,11,18,19,29	3103
permanent immunosuppression	3132
many disadvantages	3168
the present experiment	3191
we	3214
a mouse	3222
rat xenograft paradigm	3233
functions restored under transient immunosuppression	3272
functions	3272
transient immunosuppression	3297
the immunosuppressive regime	3344
MATERIAL AND METHODS Experimental Design A total of 58	3392
MATERIAL AND METHODS	3392
Experimental Design	3413
A total of 58	3433
A total	3433
58	3444
strain of adult female Albino Swiss rats -LRB- locally bred , London , UK , body weight 200 -- 220 g -RRB-	3466
strain	3466
adult female Albino Swiss rats -LRB- locally bred , London , UK , body weight 200 -- 220 g -RRB-	3476
adult female Albino Swiss rats	3476
London , UK , body weight 200 -- 220 g	3522
London , UK , body weight 200	3522
London , UK	3522
body weight 200	3534
body weight	3534
200	3546
220 g	3550
Group 1 : Twenty unlesioned rats received mouse OEC / ONF xenografts without immunosuppression .	3568
Group 1	3568
Twenty unlesioned rats	3577
mouse OEC	3609
mouse	3609
OEC	3615
ONF xenografts without immunosuppression	3620
ONF xenografts	3620
immunosuppression	3643
Histology	3662
4 days -LRB- n = 5 -RRB- , 1 -LRB- n = 5 -RRB- , 2 -LRB- n = 4 -RRB- , 3 -LRB- n = 3 -RRB- , and 4 weeks -LRB- n = 3 -RRB-	3691
4 days -LRB- n = 5 -RRB-	3691
n	3699
5	3703
1 -LRB- n = 5 -RRB-	3707
1	3707
n	3710
5	3714
2 -LRB- n = 4 -RRB-	3718
2	3718
n	3721
4	3725
3 -LRB- n = 3 -RRB-	3729
3	3729
n	3732
3	3736
4 weeks -LRB- n = 3 -RRB-	3744
n	3753
3	3757
The remaining 38 rats	3761
CST lesions	3787
DFR	3819
Group 2 : In 11/38 of these rats DFR had not been abolished , and they were sacrificed for histology .	3824
Group 2	3824
11/38 of these rats	3836
11/38	3836
these rats	3845
DFR	3856
they	3888
histology	3913
Group 3 : In 8/38 rats in which DFR was abolished , they were left for 10 -- 12 months -LRB- as a long-term control to check that DFR would not return -RRB- before sacrifice and histology .	3924
Group 3	3924
8/38 rats in which DFR was abolished	3936
8/38 rats	3936
DFR	3955
they	3974
10	3993
12 months -LRB- as a long-term control to check that DFR would not return -RRB- before sacrifice and histology	3996
12 months	3996
a long-term control	4010
DFR	4044
sacrifice and histology	4073
The remaining 19/38 rats	4098
mouse OEC/ONF xenografts	4136
8 weeks	4164
the CST lesions	4178
Cyclosporine administration	4195
daily injections	4276
Group 4 : In 6/19 rats that showed no return of DFR at 5 weeks after receiving mouse OEC transplants , they were terminated for histology .	4294
Group 4	4294
6/19 rats that showed no return of DFR at 5 weeks after receiving mouse OEC transplants	4306
6/19 rats	4306
no return of DFR at 5 weeks	4328
no return	4328
DFR at 5 weeks	4341
DFR	4341
5 weeks	4348
mouse OEC transplants	4372
they	4395
histology	4420
Group 5 : In the remaining 13/19 rats where DFR had returned after receiving mouse OEC transplants , cyclosporine injection was continued for a further 10 days after the day when DFR had returned .	4431
Group 5	4431
the remaining 13/19 rats where DFR had returned after receiving mouse OEC transplants	4443
the remaining 13/19 rats	4443
DFR	4474
mouse OEC transplants	4507
cyclosporine injection	4530
a further 10 days	4571
the day when DFR had returned	4595
the day	4595
DFR	4608
Ten days later	4626
cyclosporine	4642
DFR testing	4672
two to three times a week	4698
two to three times	4698
a week	4717
8 weeks	4730
the transplants	4754
Directed Forepaw Reaching -LRB- DFR -RRB- and Microsurgery All animals	4771
Directed Forepaw	4771
-LRB- DFR -RRB- and Microsurgery All animals	4797
-LRB- DFR -RRB-	4797
Microsurgery All animals	4807
the UK Home Office regulations ASPA 5 -LRB- 2 -RRB- PIL 70/9580 for the care and use of laboratory animals , the UK Animals -LRB- Scientific Procedures -RRB- Act 1986 with the ethical approval of the UCL Institute for Neurology	4858
the UK Home Office regulations ASPA 5 -LRB- 2 -RRB-	4858
the UK Home Office regulations	4858
ASPA 5 -LRB- 2 -RRB-	4889
ASPA 5	4889
2	4896
PIL 70/9580 for the care	4899
PIL 70/9580	4899
the care	4915
use of laboratory animals , the UK Animals -LRB- Scientific Procedures -RRB- Act 1986 with the ethical approval of the UCL Institute for Neurology	4928
use	4928
laboratory animals , the UK Animals -LRB- Scientific Procedures -RRB- Act 1986 with the ethical approval of the UCL Institute for Neurology	4935
laboratory animals	4935
the UK Animals	4955
Scientific Procedures	4971
Act 1986 with the ethical approval of the UCL Institute for Neurology	4994
Act 1986	4994
the ethical approval of the UCL Institute for Neurology	5008
the ethical approval	5008
the UCL Institute for Neurology	5032
the UCL Institute	5032
Neurology	5054
Presurgery	5065
DFR	5077
as previously described -LRB- 12 -RRB-	5097
as previously	5097
12	5122
the rats	5135
the forepaws	5164
small pieces of noodles	5189
small pieces	5189
noodles	5205
a slit in the front of the cage	5221
a slit	5221
the front of the cage	5231
the front	5231
the cage	5244
50 retrievals each session	5259
50 retrievals	5259
each session	5273
Rats that used both right and left paws -LRB- more than 15 times each -RRB-	5287
Rats	5287
both right	5302
paws -LRB- more than 15 times each -RRB-	5322
paws	5322
15 times each	5338
15 times	5338
each	5347
the CST lesions	5378
CST Lesions .	5395
CST	5395
Lesions	5399
Rats	5408
isoflurane	5436
Abbott	5448
Laboratories Ltd. , Maidenhead , and Berkshire , UK	5455
Laboratories Ltd.	5455
Maidenhead	5474
Berkshire , UK	5490
Unilateral CST lesions	5506
C1 and C2 vertebrae	5547
an electrode -LRB- LCE ; Cosman Medical Inc. , Burlington , MA , USA -RRB-	5574
an electrode	5574
LCE ; Cosman Medical Inc. , Burlington , MA , USA	5588
LCE	5588
Cosman Medical Inc. , Burlington , MA , USA	5593
The CST and adjacent gray matter	5636
The CST	5636
adjacent gray matter	5648
a heat lesion produced by a radiofrequency lesion device -LRB- RFG-3C RF ; Radionics Inc. , Burlington , MA , USA -RRB- operating at 10 V for 1 min as previously described -LRB- 32 -RRB-	5687
a heat lesion	5687
a radiofrequency lesion device -LRB- RFG-3C RF ; Radionics Inc. , Burlington , MA , USA -RRB- operating at 10 V for 1 min as previously described -LRB- 32 -RRB-	5713
a radiofrequency lesion device -LRB- RFG-3C RF ; Radionics Inc. , Burlington , MA , USA -RRB-	5713
a radiofrequency lesion device	5713
RFG-3C RF ; Radionics Inc. , Burlington , MA , USA	5745
RFG-3C RF	5745
Radionics Inc. , Burlington , MA , USA	5756
10 V for 1 min as previously described -LRB- 32 -RRB-	5806
10 V	5806
1 min as previously described -LRB- 32 -RRB-	5815
1 min	5815
32	5846
Postsurgery	5851
DFR testing	5864
3 days	5888
the lesion , two to three times a week	5901
the lesion	5901
two to three times a week	5913
two to three times	5913
a week	5932
Rats that showed complete absence of DFR for 8 weeks	5940
Rats	5940
complete absence of DFR	5957
complete absence	5957
DFR	5977
8 weeks	5985
mouse OEC transplants -LRB- Groups 4 and 5 -RRB-	6018
mouse OEC transplants	6018
Groups 4 and 5	6041
Groups 4	6041
5	6054
Eight rats with complete absence of DFR	6058
Eight rats	6058
complete absence of DFR	6074
complete absence	6074
DFR	6094
12 months as a long-term control -LRB- Group 3 -RRB-	6120
12 months	6120
a long-term control -LRB- Group 3 -RRB-	6133
a long-term control	6133
Group 3	6154
OEC Culture The tissue from the outer nerve and glomerular layers of the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6 -LRB- Harlan Laboratories , Bicester , Oxfordshire , UK -RRB- was trypsinized -LRB- 0.1 % ; Worthington Biochemical Corporation , Lakewood , NJ , USA -RRB- for 15 min at 37 °C and plated on to 35-mm Nunc ™ dishes -LRB- Thermo Fisher Scientific UK , Hertfordshire , UK -RRB-	6164
OEC Culture The	6164
tissue from the outer nerve and glomerular layers of the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6 -LRB- Harlan Laboratories , Bicester , Oxfordshire , UK -RRB-	6180
tissue from the outer nerve and glomerular layers of the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6	6180
tissue from the outer nerve	6180
tissue	6180
the outer nerve	6192
glomerular layers of the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6	6212
glomerular layers	6212
the olfactory bulbs of -LRB- n = 40 -RRB- 5-month-old female C57BL/6	6233
the olfactory bulbs	6233
n = 40	6257
n	6257
= 40	6259
5-month-old female C57BL/6	6265
Harlan Laboratories	6293
Bicester	6314
Oxfordshire , UK	6324
0.1 % ; Worthington Biochemical Corporation , Lakewood , NJ , USA	6358
0.1 %	6358
Worthington Biochemical Corporation , Lakewood , NJ , USA	6364
Worthington	6364
Biochemical	6376
Corporation , Lakewood , NJ , USA	6388
15 min	6424
37 °C	6434
35-mm Nunc ™ dishes	6456
Thermo Fisher Scientific UK	6476
Hertfordshire	6505
UK	6520
poly-d-lysine -LRB- Sigma - Aldrich , Dorset , UK -RRB-	6536
poly-d-lysine	6536
Sigma	6551
Aldrich , Dorset , UK	6558
Aldrich	6558
Dorset , UK	6567
The cells	6580
15	6610
16 days in DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB- medium	6613
16 days	6613
DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB- medium	6624
DMEM-F12 -LRB- Life Technologies Ltd , Paisley , UK -RRB-	6624
DMEM-F12	6624
Life Technologies Ltd , Paisley , UK	6634
Life Technologies Ltd	6634
Paisley , UK	6657
10 % fetal calf serum	6692
3133-028 ; Gibco , Paisley , UK	6714
3133-028	6714
Gibco , Paisley , UK	6724
The OECs	6745
p75 immunostaining -LSB- anti-nerve growth factor receptor antibody , extracellular , clone 192-IgG -LRB- MAB365 -RRB- ; Millipore Ltd Hertfordshire , UK -RSB- , and the ONFs	6773
p75 immunostaining	6773
anti-nerve growth factor receptor antibody	6793
extracellular	6837
clone 192-IgG -LRB- MAB365 -RRB-	6852
clone 192-IgG	6852
MAB365	6867
Millipore Ltd Hertfordshire	6876
UK -RSB-	6905
the ONFs	6914
FN	6939
immunostaining -LSB- polyclonal rabbit anti-human fibronectin -LRB- A0245 ; Dako Ltd , Cambridgeshire , UK -RRB- -RSB-	6943
polyclonal rabbit	6959
A0245 ; Dako Ltd , Cambridgeshire , UK	7001
A0245	7001
Dako Ltd , Cambridgeshire , UK	7008
Transplantation Two days before transplantation	7040
Transplantation	7040
Two days	7056
transplantation	7072
the cells were transfected with a GFP gene harboring lentiviral construct	7088
the cells	7088
a GFP gene	7120
lentiviral construct	7141
4,17,24	7163
The cell suspension	7173
a final concentration of 25 × 106/ml in DMEM-F12	7208
a final concentration	7208
25 × 106/ml in DMEM-F12	7233
25 × 106/ml	7233
DMEM-F12	7248
FCS	7265
Four microliters of the suspension -LRB- around 100,000 cells -RRB-	7270
Four microliters	7270
the suspension -LRB- around 100,000 cells -RRB-	7290
the suspension	7290
100,000 cells	7313
the lesion site via a glass micropipette	7347
the lesion site	7347
a glass micropipette	7367
a 100	7393
120-μm internal tip diameter	7403
transplantation	7451
cyclosporine -LRB- Novartis , Surrey , UK -RRB-	7468
cyclosporine	7468
Novartis	7482
Surrey	7492
UK	7500
15 mg/ml	7515
20 % Tween 80 solution -LRB- Sigma - Aldrich -RRB- at a dosage of 6 mg/kg with 100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB- was delivered intraperitoneally -LRB- IP -RRB- via Microfine insulin syringes -LRB- BD Ltd , Dun Laoghaire , Ireland -RRB-	7527
20 % Tween	7527
80 solution -LRB- Sigma - Aldrich -RRB- at a dosage of 6 mg/kg with 100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7537
80 solution -LRB- Sigma - Aldrich -RRB-	7537
Sigma - Aldrich	7550
Sigma	7550
Aldrich	7557
a dosage of 6 mg/kg with 100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7569
a dosage	7569
6 mg/kg with 100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7581
6 mg/kg	7581
100 % ethanol -LRB- VWR , Fontenay Sous Bois , France -RRB-	7594
100 % ethanol	7594
VWR	7608
Fontenay Sous Bois	7613
France	7633
IP	7674
Microfine insulin syringes -LRB- BD Ltd , Dun Laoghaire , Ireland -RRB-	7682
Microfine insulin syringes	7682
BD Ltd , Dun Laoghaire , Ireland	7710
BD Ltd	7710
Dun Laoghaire	7718
Ireland	7733
DFR testing	7762
3 days	7788
the transplantation	7801
two to three times weekly	7836
Immunohistochemistry Rats	7863
4 % paraformaldehyde -LRB- TAAB Laboratories Equipment Ltd , Reading , UK -RRB-	7908
4 % paraformaldehyde	7908
TAAB	7929
Laboratories Equipment Ltd , Reading , UK	7934
Laboratories Equipment Ltd	7934
Reading , UK	7962
terminal anesthesia -LSB- for details	7981
terminal anesthesia -LSB-	7981
details	8006
Keyvan-Fouladi	8019
et al. -LRB- 12 -RRB-	8034
et al.	8034
12	8042
Coronal or horizontal cryostat sections , 16 μm ,	8048
Coronal or horizontal cryostat sections	8048
Coronal	8048
horizontal cryostat sections	8059
16 μm	8089
GFP/NF -LRB- neurofilament , rabbit anti-H + L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB- ; glial fibrillary acidic protein -LRB- GFAP/NF -RRB- -LRB- mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen -RRB- ; CD45 -LRB- mouse anti-CD45 1:500 ; BD Pharmingen , Oxford , UK -RRB-	8127
GFP/NF	8127
neurofilament , rabbit anti-H + L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB- ; glial fibrillary acidic protein -LRB- GFAP/NF -RRB- -LRB- mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen -RRB- ; CD45 -LRB- mouse anti-CD45 1:500 ; BD Pharmingen , Oxford , UK	8135
neurofilament	8135
rabbit anti-H + L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB- ; glial fibrillary acidic protein -LRB- GFAP/NF -RRB- -LRB- mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen -RRB- ; CD45 -LRB- mouse anti-CD45 1:500 ; BD Pharmingen , Oxford	8150
rabbit anti-H	8150
L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB- ; glial fibrillary acidic protein -LRB- GFAP/NF -RRB- -LRB- mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen -RRB- ; CD45 -LRB- mouse anti-CD45 1:500 ; BD Pharmingen , Oxford	8164
L chain NF 1:500 ; Invitrogen , Paisley , UK -RRB-	8164
L chain NF	8164
1:500 ; Invitrogen , Paisley , UK -RRB-	8175
1:500	8175
Invitrogen , Paisley , UK	8182
Invitrogen	8182
Paisley , UK	8194
glial fibrillary acidic protein -LRB- GFAP/NF -RRB- -LRB- mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen -RRB-	8208
glial fibrillary acidic protein -LRB- GFAP/NF -RRB-	8208
glial fibrillary acidic protein	8208
GFAP/NF	8241
mouse anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen	8251
mouse	8251
anti-GFAP 1:1,000 , rabbit anti-H + L chain NF 1:500 ; Invitrogen	8257
anti-GFAP 1:1,000 , rabbit anti-H	8257
anti-GFAP 1:1,000	8257
rabbit anti-H	8276
L chain NF 1:500 ; Invitrogen	8290
L chain NF 1:500	8290
L chain NF	8290
1:500	8301
Invitrogen	8308
CD45 -LRB- mouse anti-CD45 1:500	8321
CD45	8321
mouse anti-CD45 1:500	8327
mouse	8327
1:500	8343
BD Pharmingen , Oxford	8350
BD Pharmingen	8350
Oxford	8365
UK	8373
The sections	8378
Alexa Fluor	8418
488	8430
546-conjugated goat anti-rabbit , anti-mouse , or goat anti-chicken secondary antibodies -LRB- 1:400 ; Invitrogen -RRB-	8439
546-conjugated goat anti-rabbit , anti-mouse , or goat anti-chicken secondary antibodies	8439
546-conjugated goat	8439
anti-rabbit , anti-mouse , or goat anti-chicken secondary antibodies	8459
1:400 ; Invitrogen	8527
1:400	8527
Invitrogen	8534
2 h at room temperature	8550
2 h	8550
room temperature	8557
Sytox Orange , 0.1 μM -LRB- Life Technologies Ltd -RRB-	8575
Sytox Orange	8575
0.1 μM -LRB- Life Technologies Ltd -RRB-	8589
0.1 μM	8589
Life Technologies Ltd	8597
cell counterstaining	8633
Fluorescent images	8655
a Leica	8694
confocal microscope TCS SP -LRB- Milton Keynes , UK -RRB-	8702
confocal microscope TCS SP	8702
Milton Keynes	8730
UK	8745
RESULTS Figure 1 .	8751
RESULTS	8751
Figure 1	8759
Lesions and transplanted OECs .	8769
Lesions and transplanted OECs	8769
Lesions	8769
transplanted OECs	8781
-LRB- A , B , C -RRB-	8800
A , B , C	8801
1	8816
Mouse OECs	8819
rat CST , no cyclosporine , survival time , 4 days in -LRB- A -RRB- , 1 week	8848
rat CST	8848
no cyclosporine	8857
survival time	8874
4 days in -LRB- A -RRB- , 1 week	8889
4 days	8889
-LRB- A -RRB- , 1 week	8899
-LRB- A -RRB-	8899
1 week	8904
-LRB- B -RRB- , and 3 weeks	8914
-LRB- B -RRB-	8914
3 weeks	8923
C	8935
GFP labeling , green ; Sytox Orange nuclear counterstaining , red .	8939
GFP labeling , green	8939
GFP labeling	8939
green	8953
Sytox Orange nuclear counterstaining , red	8960
Sytox Orange nuclear counterstaining	8960
red	8998
-LRB- D -RRB- Group 4 .	9003
-LRB- D -RRB-	9003
Group 4	9007
restoration of DFR , the OECs not located	9023
restoration	9023
DFR , the OECs not located	9038
DFR	9038
the OECs not located	9043
the OECs	9043
the lesion	9067
GFP labeling , green ; GFAP immunostaining , red .	9079
GFP labeling , green	9079
GFP labeling	9079
green	9093
GFAP immunostaining , red	9100
GFAP immunostaining	9100
red	9121
Survival time , 13 weeks -LRB- 8 weeks after CST lesion , 5 weeks after the transplantation -RRB- with daily cyclosporine injection .	9126
Survival time	9126
13 weeks -LRB- 8 weeks after CST lesion , 5 weeks after the transplantation -RRB- with daily cyclosporine injection	9141
13 weeks -LRB- 8 weeks after CST lesion , 5 weeks after the transplantation -RRB-	9141
8 weeks after CST lesion , 5 weeks after the transplantation	9151
8 weeks	9151
CST lesion , 5 weeks after the transplantation	9165
CST lesion	9165
5 weeks after the transplantation	9177
5 weeks	9177
the transplantation	9191
daily cyclosporine injection	9217
-LRB- E , F -RRB-	9247
E , F	9248
E	9248
F	9251
3	9260
Long-term complete lesions showing no recovery of DFR .	9263
Long-term complete lesions	9263
no recovery of DFR	9298
no recovery	9298
DFR	9313
NF/GFAP double immunostaining .	9318
NF/GFAP	9318
double immunostaining	9326
NF , red ; GFAP , green .	9349
NF , red	9349
NF	9349
red	9353
GFAP , green	9358
GFAP	9358
green	9364
Survival time , 10 months .	9371
Survival time	9371
10 months	9386
-LRB- F -RRB- High power .	9397
-LRB- F -RRB-	9397
High power	9401
G	9414
J -RRB- Group 5	9416
J	9416
Group 5	9419
Restoration of DFR after withdrawal temporary immunoprotection .	9428
Restoration	9428
DFR	9443
withdrawal temporary immunoprotection	9453
Complete destruction of the	9492
Complete destruction	9492
the	9516
cells	9532
NF/GFAP double staining .	9539
NF/GFAP	9539
double staining	9547
NF , red ; GFAP , green .	9564
NF , red	9564
NF	9564
red	9568
GFAP , green	9573
GFAP	9573
green	9579
Survival time , 16 weeks -LRB- 8 weeks after CST lesion , 8 weeks after the transplantation -RRB- .	9586
Survival time	9586
16 weeks -LRB- 8 weeks after CST lesion , 8 weeks after the transplantation -RRB-	9601
16 weeks	9601
8 weeks after CST lesion , 8 weeks after the transplantation	9611
8 weeks	9611
CST lesion , 8 weeks after the transplantation	9625
CST lesion	9625
8 weeks after the transplantation	9637
8 weeks	9637
the transplantation	9651
-LRB- H -RRB- High power .	9673
-LRB- H -RRB-	9673
High power	9677
A -- C , I , J -RRB- Horizontal sections ; -LRB- D -- H -RRB-	9690
A -- C , I , J -RRB- Horizontal sections ;	9690
C , I , J -RRB- Horizontal	9692
C , I , J -RRB-	9692
C	9692
I	9695
J	9698
sections	9712
D -- H	9723
D	9723
H	9725
sections	9734
Scale bars : 100 μm -LRB- A , B , D -RRB- , 50 μm -LRB- C , F , H , J -RRB- , 200 μm -LRB- E , G , I -RRB- .	9744
Scale bars	9744
100 μm -LRB- A , B , D -RRB- , 50 μm -LRB- C , F , H , J -RRB- , 200 μm -LRB- E , G , I -RRB-	9756
100 μm -LRB- A , B , D -RRB-	9756
A , B , D	9764
50 μm -LRB- C , F , H , J -RRB-	9774
200 μm -LRB- E , G , I -RRB-	9794
E	9802
G	9805
I	9808
Figure 2 .	9813
Figure	9813
2	9820
function	9834
rejection of xenografts	9849
rejection	9849
xenografts	9862
Number of directed forepaw reaches -LRB- DFR , ordinate , mean ± SD -RRB- in the 13 rats of Group 5 , which had complete absence of DFR for 8 weeks after an ipsilateral corticospinal tract lesion -LRB- Les -RRB- and return of DFR after mouse OEC/ONF xenografts -LRB- TR -RRB-	9874
Number	9874
forepaw reaches	9893
DFR	9910
± SD	9930
the 13 rats of Group 5 , which had complete absence of DFR for 8 weeks after an ipsilateral corticospinal tract lesion -LRB- Les -RRB-	9939
the 13 rats	9939
Group 5	9954
complete absence of DFR for 8 weeks	9973
complete absence	9973
DFR for 8 weeks	9993
DFR	9993
8 weeks	10001
an ipsilateral corticospinal tract lesion -LRB- Les -RRB-	10015
an ipsilateral corticospinal tract lesion	10015
Les	10058
return of DFR	10067
return	10067
DFR	10077
mouse OEC/ONF xenografts -LRB- TR -RRB-	10087
mouse OEC/ONF xenografts	10087
TR	10113
daily cyclosporine	10140
DFR	10160
all rats	10189
withdrawal of cyclosporine -LRB- CS/wd -RRB- at 10 days	10204
withdrawal	10204
cyclosporine -LRB- CS/wd -RRB- at 10 days	10218
cyclosporine -LRB- CS/wd -RRB-	10218
cyclosporine	10218
CS/wd	10232
10 days	10242
the first return of DFR	10256
the first return	10256
DFR	10276
Time scale , abscissa in weeks .	10281
Time scale	10281
abscissa in weeks	10293
abscissa	10293
weeks	10305
Group 1 -LRB- n = 20 -RRB- : Nonlesioned Rats Receiving Mouse OEC/ONF Xenografts Without Immune Protection After 15 -- 16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60 -- 70 % p75 + spindle - shaped bipolar or tripolar OECs and 30 -- 40 % FN + flattened , short-processed multipolar ONFs .	10313
Group 1	10313
n	10322
20	10326
Nonlesioned Rats Receiving Mouse OEC/ONF Xenografts Without Immune Protection After 15 -- 16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60 -- 70 % p75 + spindle - shaped bipolar or tripolar OECs and 30 -- 40 % FN + flattened , short-processed multipolar ONFs	10331
Nonlesioned Rats	10331
Mouse OEC/ONF Xenografts Without Immune Protection After 15 -- 16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60 -- 70 % p75 + spindle - shaped bipolar or tripolar OECs and 30 -- 40 % FN	10358
Mouse OEC/ONF Xenografts Without Immune Protection After 15 -- 16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60	10358
Mouse OEC/ONF Xenografts Without Immune Protection After 15	10358
Mouse OEC/ONF Xenografts	10358
Immune Protection	10391
15	10415
16 days in culture the biopsied mouse olfactory bulbs yielded a mixture of 60	10418
16 days	10418
culture the biopsied mouse olfactory bulbs yielded a mixture of 60	10429
culture the	10429
mouse olfactory bulbs yielded a mixture of 60	10450
mouse	10450
olfactory bulbs	10456
a mixture of 60	10480
a mixture	10480
60	10493
70 % p75 + spindle	10496
70 % p75	10496
spindle	10505
shaped bipolar or tripolar OECs	10514
30 -- 40 % FN	10550
30	10550
40 % FN	10553
short-processed multipolar ONFs	10572
This mixture	10605
the same C1/2 position in intact CST	10640
the same C1/2 position	10640
intact CST	10666
that where the lesions were carried out in the other groups	10680
that	10680
the lesions	10691
the other groups	10723
4 days	10744
the transplanted cells , identified by the GFP labeling ,	10751
the transplanted cells	10751
the GFP labeling	10789
The transplant area	10822
a compact ovoid hypercellular mass	10858
1 mm along the rostrocaudal axis of the host CST	10899
1 mm	10899
the rostrocaudal axis of the host CST	10910
the rostrocaudal axis	10910
the host CST	10935
0.3 mm	10959
the transplant	10979
the cells	10994
around 100 μm	11022
the surrounding mechanical forces , were orientated in parallel to the host CST -LRB- Fig. 1A -RRB-	11062
the surrounding mechanical forces	11062
parallel	11116
the host CST -LRB- Fig. 1A -RRB-	11128
the host CST	11128
Fig. 1A	11142
1	11155
week	11157
the numbers of GFP-labeled cells	11162
the numbers	11162
GFP-labeled cells	11177
around 30 % of those seen at 4 days	11211
around 30 %	11211
those seen at 4 days	11225
those	11225
4 days	11239
The majority of cells	11247
The majority	11247
cells	11263
their	11278
longitudinal pattern	11294
irregular blob-like shapes -LRB- Fig. 1B -RRB-	11351
irregular blob-like shapes	11351
Fig. 1B	11379
The background	11389
hollow cuffed areas suggesting an influx of host immunocytes and perivascular cuffing	11435
hollow cuffed areas	11435
an influx of host immunocytes and perivascular cuffing	11466
an influx	11466
host immunocytes and perivascular cuffing	11479
host immunocytes	11479
perivascular cuffing	11500
2 , 3 , and 4 weeks	11525
2	11525
3	11528
4 weeks	11535
no GFP-labeled cells	11543
any part of the transplanted area , which retained the hypercellularity and the hollow vascular areas -LRB- Fig. 1C -RRB-	11580
any part	11580
the transplanted area , which retained the hypercellularity and the hollow vascular areas -LRB- Fig. 1C -RRB-	11592
the transplanted area	11592
the hypercellularity and the hollow vascular areas -LRB- Fig. 1C -RRB-	11630
the hypercellularity	11630
the hollow vascular areas -LRB- Fig. 1C -RRB-	11655
the hollow vascular areas	11655
Fig. 1C	11682
2 weeks	11695
immunostaining of CD45 -LRB- leukocyte common antigen -RRB-	11703
immunostaining of CD45	11703
immunostaining	11703
CD45	11721
leukocyte common antigen	11727
leukocyte	11727
common antigen	11737
cells intimately associated with the vessel walls	11760
cells	11760
the vessel walls	11793
diapedesis of immunocytes infiltrating the entire transplant mass	11822
diapedesis	11822
immunocytes infiltrating the entire transplant mass	11836
immunocytes	11836
the entire transplant mass	11861
Thirty-eight rats -LRB- Groups 2 -- 5 -RRB-	11889
Thirty-eight rats	11889
Groups 2 -- 5	11908
Groups 2	11908
5	11917
DFR	11936
the basis that on 50 trials the DFR was comparable on the two sides -LRB- maximum imbalance 35/15 -RRB-	11943
the basis	11943
50 trials	11961
the DFR	11971
the two sides	11997
maximum imbalance 35/15	12012
maximum imbalance	12012
35/15	12030
Unilateral C1/2 CST lesions	12038
DFR	12082
3 days	12115
operation	12128
Group 2 : Rats With Failed CST Lesions -LRB- n = 11 -RRB- In 11 of these rats DFR started to return within 2 weeks .	12139
Group 2	12139
Rats With Failed CST Lesions -LRB- n = 11 -RRB- In 11 of these rats DFR started to return within 2 weeks	12148
Rats	12148
CST	12165
Lesions -LRB- n = 11 -RRB-	12169
Lesions	12169
n	12178
11	12182
11 of these rats	12189
11	12189
these rats	12195
DFR	12206
2 weeks	12235
These rats	12244
the histology	12276
all 11 cases	12308
the destruction of the CST	12321
the destruction	12321
the CST	12340
The remaining 27 rats -LRB- Groups 3 -- 5 -RRB-	12364
The remaining 27 rats	12364
Groups 3 -- 5	12387
Groups 3	12387
5	12396
complete loss of DFR	12406
complete loss	12406
DFR	12423
8 weeks	12430
operation	12444
Group 3 : Rats Confirming Long-Term Persistence of Loss of DFR -LRB- n = 8 -RRB- In the eight rats of this group DFR testing was continued two to three times a week for 10 months -LRB- n = 3 -RRB- or 12 months -LRB- n = 5 -RRB- .	12455
Group 3	12455
Rats Confirming Long-Term Persistence of Loss of DFR -LRB- n = 8 -RRB- In the eight rats of this group DFR testing was continued two to three times a week for 10 months -LRB- n = 3 -RRB- or 12 months -LRB- n = 5 -RRB-	12464
Rats	12464
Long-Term Persistence of Loss of DFR -LRB- n = 8 -RRB- In the eight rats of this group DFR testing was continued two to three times a week for 10 months -LRB- n = 3 -RRB- or 12 months -LRB- n = 5 -RRB-	12480
Long-Term Persistence	12480
Loss of DFR -LRB- n = 8 -RRB-	12505
Loss	12505
DFR -LRB- n = 8 -RRB-	12513
DFR	12513
n	12518
8	12522
the eight rats of this group	12528
the eight rats	12528
this group	12546
DFR testing	12557
two to three times	12583
a week	12602
10 months -LRB- n = 3 -RRB- or 12 months -LRB- n = 5 -RRB-	12613
10 months -LRB- n = 3 -RRB-	12613
n	12624
3	12628
12 months -LRB- n = 5 -RRB-	12634
n	12645
5	12649
no time	12656
there	12668
any spontaneous recovery of DFR on the lesioned side in any of these eight rats	12674
any spontaneous recovery	12674
DFR on the lesioned side in any of these eight rats	12702
DFR	12702
the lesioned side in any of these eight rats	12709
the lesioned side	12709
any of these eight rats	12730
any	12730
these eight rats	12737
Even at the longer survivals none of the eight rats	12755
Even at the longer survivals none	12755
the longer survivals	12763
the eight rats	12792
any diminution of DFR	12814
any diminution	12814
DFR	12832
the unlesioned side	12839
Immunostaining	12860
all these rats	12890
complete destruction of the CST	12909
complete destruction	12909
the CST	12933
partial destruction of the adjacent gray matter	12946
partial destruction	12946
the adjacent gray matter	12969
two cases spreading into part of the ventral column	13001
two cases	13001
part of the ventral column	13026
part	13026
the ventral column	13034
Immunostaining for astrocytes -LRB- GFAP -RRB- and axons -LRB- neurofilament , NF -RRB-	13054
Immunostaining	13054
astrocytes -LRB- GFAP -RRB- and axons -LRB- neurofilament , NF -RRB-	13073
astrocytes	13073
GFAP	13085
axons	13095
neurofilament , NF	13102
neurofilament	13102
NF	13117
the lesion center	13133
any trace of NF staining	13176
any trace	13176
NF staining	13189
the NF + axons of the surrounding spinal tissue by a thick layer of scarred	13236
the NF	13236
axons of the surrounding spinal tissue by a thick layer of scarred	13244
axons	13244
the surrounding spinal tissue by a thick layer of scarred	13253
the surrounding spinal tissue	13253
a thick layer of scarred	13286
a thick layer	13286
scarred	13303
GFAP + astrocytes -LRB- Fig. 1E -RRB-	13311
GFAP + astrocytes	13311
Fig. 1E	13329
The remaining 19 rats with no DFR at 8 weeks after lesion	13339
The remaining 19 rats	13339
no DFR at 8 weeks after lesion	13366
no DFR	13366
8 weeks after lesion	13376
8 weeks	13376
lesion	13390
mouse OEC/ONF mixtures transplanted into the lesion site followed by immunoprotection by daily cyclosporine -LRB- Groups 4 and 5 -RRB-	13406
mouse OEC/ONF mixtures	13406
the lesion site followed by immunoprotection by daily cyclosporine -LRB- Groups 4 and 5 -RRB-	13447
the lesion site	13447
immunoprotection	13475
daily cyclosporine -LRB- Groups 4 and 5 -RRB-	13495
daily cyclosporine	13495
Groups 4 and 5	13515
Groups 4	13515
5	13528
DFR testing	13532
3 days	13556
the transplants	13579
two to three times a week	13611
two to three times	13611
a week	13630
Group 4 : Rats With Grafts Failing to Restore DFR Six of these cyclosporine-treated rats in which DFR had not returned after 5 weeks were terminated .	13638
Group 4	13638
Rats With Grafts Failing to Restore DFR Six of these cyclosporine-treated rats in which DFR had not returned after 5 weeks were terminated	13647
Rats	13647
Grafts Failing to Restore DFR Six of these cyclosporine-treated rats in which DFR had not returned after 5 weeks were terminated	13657
Grafts	13657
DFR Six of these cyclosporine-treated rats in which DFR had not returned after 5 weeks were terminated	13683
DFR Six	13683
these cyclosporine-treated rats in which DFR had not returned after 5 weeks were terminated	13694
these cyclosporine-treated rats	13694
DFR	13735
5 weeks	13762
Immunohistochemistry	13787
all six	13820
complete destruction of the CST and partial destruction of the adjacent gray matter	13832
complete destruction of the CST	13832
complete destruction	13832
the CST	13856
partial destruction of the adjacent gray matter	13868
partial destruction	13868
the adjacent gray matter	13891
no transplanted cells and no NF staining	13921
no transplanted cells	13921
no NF staining	13947
the CST lesion center , which was walled off by a heavy GFAP + astrocytic scar	13978
the CST lesion center	13978
a heavy GFAP + astrocytic scar	14025
a heavy GFAP	14025
astrocytic scar	14039
GFP labeling	14056
cyclosporine treatment	14087
the xenografted mouse cells	14110
compact masses elongated along the rostrocaudal axis of the host spinal cord -LRB- as in the short-term animals of Group 1 -RRB-	14165
compact masses	14165
the rostrocaudal axis of the host spinal cord -LRB- as in the short-term animals of Group 1 -RRB-	14196
the rostrocaudal axis	14196
the host spinal cord -LRB- as in the short-term animals of Group 1 -RRB-	14221
the host spinal cord	14221
the short-term animals of Group 1	14249
the short-term animals	14249
Group 1	14275
These six transplants	14285
the scar walling	14328
the CST lesion area	14349
a position to bridge the lesion	14395
the lesion	14416
Two transplants	14428
the ascending dorsal column above the CST	14460
the ascending dorsal column	14460
the CST	14494
one	14503
the ventral spinal cord	14514
three	14543
the gray matter	14557
the CST -LRB- Fig. 1D -RRB-	14585
the CST	14585
Fig. 1D	14594
These transplants	14604
the ingrowth of local NF + axons from the surrounding area	14634
the ingrowth of local NF	14634
the ingrowth	14634
local NF	14650
axons from the surrounding area	14660
axons	14660
the surrounding area	14671
Group 5 : Rats With Return of DFR -LRB- n = 13 -RRB- With Mouse OEC/ONF Xenografts Initially Protected by Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB- .	14693
Group 5	14693
Rats With Return of DFR -LRB- n = 13 -RRB- With Mouse OEC/ONF Xenografts Initially Protected by Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14702
Rats	14702
Return of DFR -LRB- n = 13 -RRB- With Mouse OEC/ONF Xenografts Initially Protected by Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14712
Return	14712
DFR -LRB- n = 13 -RRB- With Mouse OEC/ONF Xenografts Initially Protected by Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14722
DFR -LRB- n = 13 -RRB-	14722
DFR	14722
n	14727
13	14731
Mouse OEC/ONF Xenografts Initially Protected by Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14740
Mouse OEC/ONF Xenografts	14740
Cyclosporine , Which Was Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14788
Cyclosporine	14788
Later Withdrawn In 13 rats the cyclosporine-protected mouse OEC/ONF transplants had restored DFR within 2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14812
Later Withdrawn	14812
13 rats	14831
the cyclosporine-protected mouse OEC/ONF transplants	14839
DFR	14905
2 weeks -LRB- n = 11 -RRB- and 3 weeks -LRB- n = 2 -RRB-	14916
2 weeks -LRB- n = 11 -RRB-	14916
n	14925
11	14929
3 weeks -LRB- n = 2 -RRB-	14937
n	14946
2	14950
DFR	14959
cyclosporine and DFR testing	14987
a further 10 days , at which point cyclosporine administration was terminated and testing continued until 8 weeks after the time of transplantation	15035
a further 10 days	15035
cyclosporine administration	15069
testing	15116
8 weeks	15140
the time of transplantation	15154
the time	15154
transplantation	15166
all 13 rats	15186
DFR	15198
5	15216
6 weeks	15218
withdrawal of cyclosporine	15232
withdrawal	15232
cyclosporine	15246
a continuous increase -LRB- Fig. 2 -RRB-	15268
a continuous increase	15268
Fig. 2	15291
The histology	15300
all the spinal cords in this group	15326
all the spinal cords	15326
this group	15350
complete destruction of CST and partial destruction of the adjacent gray matter	15365
complete destruction of CST	15365
complete destruction	15365
CST	15389
partial destruction of the adjacent gray matter	15397
partial destruction	15397
the adjacent gray matter	15420
Groups 3 and 4	15451
the rats of Group 1 -LRB- Fig. 1C -RRB- , at 3 weeks after transplantation	15473
the rats of Group 1 -LRB- Fig. 1C -RRB-	15473
the rats	15473
Group 1	15485
Fig. 1C	15494
3 weeks	15507
transplantation	15521
none of the xenografted cells	15538
none	15538
the xenografted cells	15546
the	15546
cells	15562
double immunostaining of GFAP/NF	15591
double immunostaining	15591
GFAP/NF	15616
every case	15639
NF + axons	15650
NF	15650
axons	15654
the lesion center -LRB- Fig. 1G -- J -RRB-	15681
the lesion center	15681
Fig. 1G -- J	15700
Fig. 1G	15700
J	15708
there	15724
317.14 ± 35.62 NF + fibers per section in the n = 7 spinal cords cut in cross section -LSB- this was surprisingly close to the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants into complete CST lesions -LRB- 12 -RRB- -RSB-	15735
317.14 ± 35.62 NF	15735
317.14	15735
35.62 NF	15744
fibers per section in the n = 7 spinal cords cut in cross section -LSB- this was surprisingly close to the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants into complete CST lesions -LRB- 12 -RRB- -RSB-	15754
fibers	15754
section in the n = 7 spinal cords cut in cross section -LSB- this was surprisingly close to the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants into complete CST lesions -LRB- 12 -RRB- -RSB-	15765
section	15765
the n = 7 spinal cords cut in cross section -LSB- this was surprisingly close to the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants into complete CST lesions -LRB- 12 -RRB- -RSB-	15776
the n	15776
= 7 spinal cords cut in cross section -LSB- this was surprisingly close to the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants into complete CST lesions -LRB- 12 -RRB-	15782
= 7 spinal cords	15782
cross section	15806
this	15821
the estimate of 320 regenerating axons in our previous rat-to-rat OEC transplants	15852
the estimate	15852
320 regenerating axons in our previous rat-to-rat OEC transplants	15868
320 regenerating axons	15868
our previous rat-to-rat OEC transplants	15894
complete CST lesions -LRB- 12 -RRB-	15939
complete CST lesions	15939
12	15961
The GFAP + scar tissue	15967
The GFAP	15967
scar tissue	15977
the cases	16012
lesion alone -LRB- Group 3 -RRB-	16027
lesion alone	16027
Group 3	16041
some astrocytes	16056
fine processes	16082
the margins of the lesion	16102
the margins	16102
the lesion	16117
DISCUSSION Olfactory ensheathing cells	16130
the olfactory nerves	16179
their origin in the olfactory mucosa	16205
their origin	16205
the olfactory mucosa	16221
all the way through the cribriform plate to their intracranial termination	16242
all the way	16242
the cribriform plate to their intracranial termination	16262
the cribriform plate	16262
their intracranial termination	16286
the olfactory bulb -LRB- 5,23 -RRB-	16320
the olfactory bulb	16320
5,23	16340
Unfortunately , with our current procedures cultures from the mucosal area yield much smaller proportions of OECs -LRB- 13 -RRB- than those from the bulb .	16347
Unfortunately , with our current procedures cultures from the mucosal area yield	16347
Unfortunately , with our current procedures cultures	16347
our current procedures	16367
the mucosal area yield	16404
much smaller proportions of OECs -LRB- 13 -RRB- than those from the bulb	16427
much smaller proportions	16427
OECs -LRB- 13 -RRB- than those from the bulb	16455
OECs -LRB- 13 -RRB-	16455
OECs	16455
13	16461
those from the bulb	16470
those	16470
the bulb	16481
straight comparisons with bulbarsourced cultures	16494
straight comparisons	16494
bulbarsourced cultures	16520
transplantation of mucosal-sourced cultures	16544
transplantation	16544
mucosal-sourced cultures	16563
regeneration of cut axons	16616
regeneration	16616
cut axons	16632
rat CST -LRB- 31 -RRB- , rat dorsal roots -LRB- 9 -RRB-	16645
rat CST -LRB- 31 -RRB-	16645
rat CST	16645
31	16654
rat dorsal roots -LRB- 9 -RRB-	16659
rat dorsal roots	16659
9	16677
three cases in a human clinical trial -LRB- 25 -RRB-	16688
three cases	16688
a human clinical trial -LRB- 25 -RRB-	16703
a human clinical trial	16703
25	16727
expansion	16743
added growth factors -LRB- 3,6 -RRB-	16756
added growth factors	16756
3,6	16778
It	16784
this	16808
the lower proportions of OECs or an intrinsic difference between the OECs at these two levels -LRB- 30 -RRB-	16822
the lower proportions of OECs	16822
the lower proportions	16822
OECs	16847
an intrinsic difference between the OECs at these two levels -LRB- 30 -RRB-	16855
an intrinsic difference	16855
the OECs at these two levels -LRB- 30 -RRB-	16887
the OECs	16887
these two levels -LRB- 30 -RRB-	16899
these two levels	16899
30	16917
the best of our knowledge	16925
the best	16925
our knowledge	16937
the only spinal injured patient who has received autologous bulbar OECs	16951
the only spinal injured patient	16951
autologous bulbar OECs	17000
a pattern of functional recovery highly suggestive of fiber regeneration	17030
a pattern	17030
functional recovery highly suggestive	17043
functional recovery	17043
fiber regeneration	17084
the injury site -LRB- 26 -RRB-	17110
the injury site	17110
26	17127
This patient	17132
a near complete severance of the midthoracic spinal cord with stump separation of 7 -- 8 mm	17149
a near complete severance of the midthoracic spinal cord with stump separation of 7	17149
a near complete severance	17149
the midthoracic spinal cord with stump separation of 7	17178
the midthoracic spinal cord	17178
stump separation of 7	17211
stump separation	17211
7	17231
8 mm	17233
his case	17242
500,000 cells	17251
culture of a single olfactory bulb	17285
culture	17285
a single olfactory bulb	17296
this number of cells	17324
this number	17324
cells	17339
a bridge	17370
an injury of this size	17386
an injury	17386
this size	17399
the cells	17410
the margins of the stumps	17439
the margins	17439
the stumps	17454
peripheral nerve strips	17504
The mechanics of future clinical cell transplantation	17529
The mechanics	17529
future clinical cell transplantation	17546
larger numbers of cells	17612
larger numbers	17612
cells	17630
Allografts using banks of human bulbar OECs or cell lines	17652
Allografts	17652
banks of human bulbar OECs or cell lines	17669
banks	17669
human bulbar OECs or cell lines	17678
human bulbar OECs	17678
cell lines	17699
an attractive possibility	17724
this problem	17761
the drawbacks of having to source cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17795
the drawbacks	17795
to source cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17819
source	17822
cells from the patient 's own olfactory bulb -LRB- 16 -RRB-	17829
cells	17829
the patient 's own olfactory bulb -LRB- 16 -RRB-	17840
the patient 's own olfactory bulb	17840
the patient 's	17840
16	17874
Protection of immunoincompatible grafts	17879
Protection	17879
immunoincompatible grafts	17893
all the side effects of requiring the use of immunosuppressive drug regimes	17928
all the side effects	17928
the use of immunosuppressive drug regimes	17962
the use	17962
immunosuppressive drug regimes	17973
Such permanent immunosuppression	18005
situations	18056
the grafted tissue	18073
an essential function -LRB- as heart , kidney , or pancreatic insulin-secreting cells -RRB-	18118
an essential function	18118
heart , kidney , or pancreatic insulin-secreting cells	18144
heart	18144
kidney	18151
pancreatic insulin-secreting cells	18162
the recovery of function in the rat CST lesion model	18208
the recovery	18208
function in the rat CST lesion model	18224
function	18224
the rat CST lesion model	18236
new fiber connections being formed by the host axons	18272
new fiber connections	18272
the host axons	18310
this recovery	18335
the transplanted OECs	18364
it	18387
the OECs	18411
the period of providing a bridge for fiber regeneration	18446
the period	18446
a bridge for fiber regeneration	18470
a bridge	18470
fiber regeneration	18483
this	18514
we	18519
a mouse	18536
rat xenograft paradigm	18547
We	18571
12,32	18583
total unilateral destruction of the dorsal CST and the adjacent medial gray matter at the C1/2 level	18601
total unilateral destruction of the dorsal CST	18601
total unilateral destruction	18601
the dorsal CST	18633
the adjacent medial gray matter at the C1/2 level	18652
the adjacent medial gray matter	18652
the C1/2 level	18687
there	18702
no return of DFR for up to 12 months -LSB- cf.	18712
no return	18712
DFR for up to 12 months	18725
DFR	18725
up to 12 months	18733
e.g. , -LRB- 2,20 -RRB-	18755
e.g.	18755
2,20	18762
The present series	18770
the transplants	18815
a bridge across the lesion area	18836
a bridge	18836
the lesion area	18852
there	18868
no return of function	18877
no return	18877
function	18890
all 13 rats with CST lesions	18903
all 13 rats	18903
CST lesions	18920
loss of DFR	18943
loss	18943
DFR	18951
the transplantation of immunoprotected mouse OEC/ONF xenografts	18955
the transplantation	18955
immunoprotected mouse OEC/ONF xenografts	18978
recovery of DFR	19028
recovery	19028
DFR	19040
This	19045
a number of previous studies showing that reparative OEC signaling mechanisms are conserved across widely different species -LRB- 10,11,18,19,29 -RRB-	19059
a number	19059
previous studies showing that reparative OEC signaling mechanisms are conserved across widely different species -LRB- 10,11,18,19,29 -RRB-	19071
previous studies	19071
reparative OEC signaling mechanisms	19101
widely different species -LRB- 10,11,18,19,29 -RRB-	19158
widely different species	19158
10,11,18,19,29	19184
all these rats	19204
the restored function	19219
the grafted cells	19262
an immune attack following removal of the immunosuppressive regime	19312
an immune attack	19312
removal of the immunosuppressive regime	19339
removal	19339
the immunosuppressive regime	19350
the OECs	19391
function	19414
their continued presence	19424
the function	19469
the intimacy of the association between the transplanted OECs -LRB- 14 -RRB- and the regenerating fibers , the rejection	19508
the intimacy	19508
the association between the transplanted OECs -LRB- 14 -RRB- and the regenerating fibers , the rejection	19524
the association	19524
the transplanted OECs -LRB- 14 -RRB- and the regenerating fibers , the rejection	19548
the transplanted OECs -LRB- 14 -RRB-	19548
the transplanted OECs	19548
14	19571
the regenerating fibers , the rejection	19579
the regenerating fibers	19579
the rejection	19604
mechanism	19618
such precision	19638
a functionally effective number of regenerating CST fibers	19658
a functionally effective number	19658
regenerating CST fibers	19693
an immune attack completely destroying the xenografted mouse OECs	19726
an immune attack	19726
the xenografted mouse OECs	19765
Histological analysis	19793
the return of function	19826
the return	19826
function	19840
the 2 -- 300 fibers present in the lesion center	19870
the 2 -- 300 fibers present	19870
the 2	19870
300 fibers	19876
the lesion center	19898
rejection of the xenografted mouse cells	19922
rejection	19922
the xenografted mouse cells	19935
This	19964
the number of CST fibers , which restored DFR in a previous study -LRB- 12 -RRB-	19986
the number	19986
CST fibers , which restored DFR in a previous study -LRB- 12 -RRB-	20000
CST fibers	20000
DFR in a previous study -LRB- 12 -RRB-	20027
DFR	20027
a previous study -LRB- 12 -RRB-	20034
a previous study	20034
12	20052
a similar study -LRB- 1 -RRB-	20060
a similar study	20060
1	20077
researchers	20080
rat Schwann cells xenografted into mouse peripheral nerve under immunosuppressive conditions	20104
rat Schwann cells	20104
mouse peripheral nerve under immunosuppressive conditions	20139
mouse peripheral nerve	20139
immunosuppressive conditions	20168
the host fibers	20208
the host fibers	20233
subsequent rejection of the foreign myelinating cells -LRB- Aguayo personal communication -RRB-	20258
subsequent rejection	20258
the foreign myelinating cells -LRB- Aguayo personal communication -RRB-	20282
the foreign myelinating cells	20282
Aguayo personal communication	20313
Aguayo	20313
personal communication	20320
The importance of our present finding	20345
The importance	20345
our present finding	20363
it	20391
the possibility of using transient immunoprotection of allografted cells	20400
the possibility	20400
transient immunoprotection of allografted cells	20425
transient immunoprotection	20425
allografted cells	20455
the surgical repair of large human spinal cord injuries	20478
the surgical repair	20478
large human spinal cord injuries	20501
the ability to use allografted cells or cell lines	20534
allografted cells or cell lines	20553
an approach	20599
the numerical restriction of autologously sourced cells	20628
the numerical restriction	20628
autologously sourced cells	20657
